MLS Pharma SRL
The score of MLS Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +228 % Total assets +273 %
Accounts of the company itself (not consolidated).
The full file covers 4 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
MLS Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Net result | 197,555 € | |||
| Equity | 437,939 € | |||
| Cash | 544,618 € | |||
| EBITDA | 253,795 € | |||
| Total assets | 662,546 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 06 Jul 2026
- Year ended 31 Dec 2024filed on 08 Aug 2025
- Year ended 31 Dec 2023filed on 26 Aug 2024
- Year ended 31 Dec 2022filed on 30 Aug 2023
MLS Pharma's financial analysis
- Solvency66.1%sector median: 58.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of MLS Pharma
MLS Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0781.947.583
- VAT number
- BE0781947583
- Peppol
- Registered · 0208:0781947583 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 14 Feb 2022
- Registered office
- 4121 Neupré
- Latest accounts
- 2025 · filed on 06 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
MLS Pharma (SRL) has been based in Neupré since 2022, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 197,555 € and equity of 437,939 €; its revenue is not published. Its solvency stands at 66.1%, above the median of its sector (58.2%).
Companies similar to MLS Pharma
Companies in the same business, of comparable size and area, outside its group.
- Docteur Quentin Lommel Clavier · balance sheet 662,554 €
- Celivinc Beloeil · balance sheet 662,510 €
- Dromo Rental and operating of own or leased real estate Eupen · balance sheet 662,585 €
- Baki Medic Charleroi · balance sheet 662,617 €
- SRL Digestive Tract Unit Auderghem · balance sheet 662,468 €
- Apple Real Estate Rental and operating of own or leased real estate Aartselaar · balance sheet 662,454 €
- Barimben Rental and operating of own or leased real estate Tremelo · balance sheet 662,443 €
- Immo DE Wildt Rental and operating of own or leased real estate Hamont-Achel · balance sheet 662,432 €
Frequently asked questions about MLS Pharma
What is the revenue of MLS Pharma?
MLS Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of MLS Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0781947583 for MLS Pharma, if the company is VAT-registered. Its company number (CBE) is 0781.947.583.
Where is the registered office of MLS Pharma?
According to the CBE register, the registered office of MLS Pharma is in 4121 Neupré.
What is the equity of MLS Pharma?
At the close of the 2025 financial year, the equity of MLS Pharma amounts to 437,939 €, a solvency of 66.1% of total assets.
Who manages MLS Pharma?
The register lists 1 active mandates at MLS Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of MLS Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →